INOVIO Reports Financial Results for Q2 2025 and Strategic Advances in DNA Medicine Development

INOVIO Reports Financial Results and Updates for Q2 2025

INOVIO Pharmaceuticals, a prominent player in the biotechnology sector, has released its financial outcomes for the second quarter of 2025, alongside significant business advancements. The company's focus remains on developing DNA medicines aimed at treating diseases linked to human papillomavirus (HPV), cancer, and infectious diseases.

Overview of Financial Results

In Q2 of 2025, INOVIO achieved a notable milestone; the company reported a decrease in Research and Development (R&D) expenses, which dropped from $23.1 million in 2024 to $14.5 million. This reduction is attributed primarily to lower costs in drug manufacturing and clinical studies involving INO-3107. General and Administrative (G&A) expenses also saw a decline, falling from $10.2 million to $8.6 million during the same period. Consequently, total operating expenses decreased to $23.1 million, reflecting streamlined operations and financial discipline.

The company recorded a net loss of $23.5 million, or $0.61 per share, an improvement compared to a net loss of $32.2 million in Q2 of 2024, signaling potential recovery and efficiency gains in operational capabilities.

Strategic Focus on INO-3107

A focal point of INOVIO's report is its ongoing efforts to submit a Biologics License Application (BLA) for INO-3107, specifically targeting Recurrent Respiratory Papillomatosis (RRP). The company successfully completed design verification testing for its CELLECTRA 5PSP device, which is a critical component in the BLA submission process. INOVIO has also applied for a rolling submission to the FDA, leveraging its breakthrough therapy designation, aiming for acceptance by the end of 2025.

Dr. Jacqueline Shea, INOVIO's President and CEO, expressed optimism regarding INO-3107’s potential as a preferred treatment for patients with RRP, highlighting the significant clinical benefits observed in long-term studies. Results from a retrospective study published in The Laryngoscope show that patients treated with INO-3107 experienced increased rates of surgery reduction over time—improving from a 72% surgery reduction rate in the first year to 86% in the second year—and a growing percentage of patients achieving complete responses.

Advancements in DNA Medicines

In addition to efforts regarding INO-3107, INOVIO unveiled promising data on next-generation DNA medicine technologies at the recent Orphan Drug Summit. These advancements include DNA-encoded monoclonal antibodies focused on tackling COVID-19, showcasing the company’s commitment to innovative therapeutic strategies. The presentation also discussed the development of DNA-encoded protein technologies designed for long-term therapeutic applications.

INOVIO plans to continue sharing updates on INO-3107 and its broader pipeline at several upcoming conferences, including the American Academy of Otolaryngology and the European Society for Medical Oncology, among others.

Financial Sustainability and Future Outlook

Financially, INOVIO has fortified its balance sheet with a recent public offering, yielding approximately $22.5 million. The company believes that its current cash reserves, bolstered by this offering, will sustain operations into the second quarter of 2026, despite an anticipated net cash burn of about $22 million for Q3 2025.

INOVIO’s commitment to advancing its clinical portfolio, particularly with INO-3107, is unwavering, as the company aims for regulatory approval and potential market launch in 2026. Moving forward, INOVIO stands poised to become a significant player in the control and treatment of HPV-related health challenges with their innovative DNA medicine technologies.

For further information, including detailed financials and operational insights, visit INOVIO’s investor relations website at INOVIO Invest.